Details of the Drug Transporter (DTP)

General Information of Drug Transporter (DTP) (ID: DT06JWZ)

DTP Name Organic anion transporter 4 (SLC22A11)
Gene Name SLC22A11
UniProt ID
Q9NSA0 (S22AB_HUMAN)
VARIDT ID
DTD0026
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Synonyms OAT4; SLC22A11; Solute carrier family 22 member 11; hOAT4
DTP Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity Detected in placenta and kidney.
Sequence
MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTHMLDNGSAV
STNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYD
RSVFTSTIVAKWDLVCSSQGLKPLSQSIFMSGILVGSFIWGLLSYRFGRKPMLSWCCLQL
AVAGTSTIFAPTFVIYCGLRFVAAFGMAGIFLSSLTLMVEWTTTSRRAVTMTVVGCAFSA
GQAALGGLAFALRDWRTLQLAASVPFFAISLISWWLPESARWLIIKGKPDQALQELRKVA
RINGHKEAKNLTIEVLMSSVKEEVASAKEPRSVLDLFCVPVLRWRSCAMLVVNFSLLISY
YGLVFDLQSLGRDIFLLQALFGAVDFLGRATTALLLSFLGRRTIQAGSQAMAGLAILANM
LVPQDLQTLRVVFAVLGKGCFGISLTCLTIYKAELFPTPVRMTADGILHTVGRLGAMMGP
LILMSRQALPLLPPLLYGVISIASSLVVLFFLPETQGLPLPDTIQDLESQKSTAAQGNRQ
EAVTVESTSL
Function This transporter mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Endogenous Substrate(s) Dehydroepiandrosterone sulfate; Diuretics; Na+; Bile salts; Dehydroepiandrosterone sulfate
TCDB ID
2.A.1.19.10
Gene ID
55867
Reactome Pathway
Organic anion transport (R-HSA-561048 )

Molecular Interaction Atlas (MIA) of This DTP

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTP
9 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bumetanide DMRV7H0 Congestive heart failure BD10 Approved [1]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Estrone sulfate DMVBIZL Atrophic vaginitis GA30.2 Approved [3]
L-Glutamic Acid DM4PUDW Schizophrenia 6A20 Approved [4]
Levocetirizine DMQYLGP Allergic rhinitis CA08.0 Approved [5]
Methotrexate DM2TEOL Anterior urethra cancer Approved [6]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [7]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [8]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Approved Drug(s)
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [2]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
3R14S-OCHRATOXIN A DM2KEW6 Discovery agent N.A. Investigative [10]
uric acid DMA1MKT Discovery agent N.A. Investigative [11]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTP

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTP
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 6.40E-01 -5.39E-02 -1.79E-01
Adrenocortical carcinoma 2D11.Z Kidney 8.79E-01 -1.26E-01 -1.82E-01
Alopecia ED70 Skin from scalp 3.72E-02 -9.47E-02 -4.93E-01
Alzheimer's disease 8A20 Entorhinal cortex 4.61E-04 -7.04E-02 -3.49E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 2.62E-01 -2.42E-01 -1.10E+00
Aortic stenosis BB70 Calcified aortic valve 4.34E-01 3.72E-01 5.43E-01
Apnea 7A40 Hyperplastic tonsil 2.12E-01 -1.57E-01 -8.27E-01
Arthropathy FA00-FA5Z Peripheral blood 5.35E-01 1.40E-02 7.36E-02
Asthma CA23 Nasal and bronchial airway 4.31E-03 -1.17E-01 -3.95E-01
Atopic dermatitis EA80 Skin 5.82E-01 -1.98E-02 -1.27E-01
Autism 6A02 Whole blood 6.35E-01 -1.96E-03 -4.90E-03
Autoimmune uveitis 9A96 Peripheral monocyte 2.87E-01 -2.71E-01 -1.49E+00
Autosomal dominant monocytopenia 4B04 Whole blood 6.02E-01 7.41E-02 3.98E-01
Bacterial infection of gingival 1C1H Gingival tissue 1.27E-01 3.04E-02 1.11E-01
Batten disease 5C56.1 Whole blood 8.65E-01 -1.45E-02 -1.28E-01
Behcet's disease 4A62 Peripheral blood 3.28E-01 1.14E-01 4.37E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 5.86E-01 -2.08E-02 -1.23E-01
Bladder cancer 2C94 Bladder tissue 3.10E-04 6.13E-01 1.98E+00
Breast cancer 2C60-2C6Z Breast tissue 7.77E-09 -1.33E-01 -3.72E-01
Cardioembolic stroke 8B11.20 Whole blood 1.67E-04 1.21E-01 6.12E-01
Cervical cancer 2C77 Cervical tissue 3.93E-01 4.09E-03 1.12E-02
Childhood onset rheumatic disease FA20.Z Peripheral blood 9.70E-01 9.40E-03 2.71E-02
Chronic hepatitis C 1E51.1 Whole blood 8.40E-01 1.38E-04 5.40E-04
Chronic obstructive pulmonary disease CA22 Lung tissue 5.66E-02 5.09E-02 2.04E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 4.14E-01 5.87E-03 2.63E-02
Chronic rhinosinusitis CA0A Sinus mucosa tissue 1.66E-01 8.33E-02 4.59E-01
Colon cancer 2B90 Colon tissue 9.45E-02 1.82E-02 5.90E-02
Coronary artery disease BA80-BA8Z Peripheral blood 5.92E-01 -1.22E-01 -4.08E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 2.05E-02 -1.13E-01 -3.35E-01
Endometriosis GA10 Endometrium tissue 2.91E-01 9.91E-02 3.18E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 9.50E-01 -2.48E-03 -1.08E-02
Familial hypercholesterolemia 5C80.00 Whole blood 3.76E-03 -3.49E-01 -8.70E-01
Gastric cancer 2B72 Gastric tissue 9.61E-01 -3.67E-02 -5.95E-01
Glioblastopma 2A00.00 Nervous tissue 4.82E-06 -1.24E-01 -3.70E-01
Glioma 2A00.0Y-2A00.0Z White matter tissue 6.77E-05 -4.29E-01 -3.07E+00
Head and neck cancer 2D42 Head and neck tissue 1.44E-03 9.52E-02 3.85E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 2.63E-01 -7.85E-02 -2.11E-01
Huntington's disease 8A01.10 Whole blood 1.57E-01 8.42E-04 4.24E-03
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 3.18E-01 -1.53E-01 -6.16E-01
Immunodeficiency 4A00-4A20 Peripheral blood 9.91E-02 6.69E-02 3.89E-01
Influenza 1.00E+30 Whole blood 6.09E-03 2.80E-01 2.45E+00
Interstitial cystitis GC00.3 Bladder tissue 7.31E-01 8.75E-02 4.42E-01
Intracranial aneurysm 8B01.0 Intracranial artery 4.92E-01 -3.38E-02 -1.72E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 4.48E-01 -6.78E-03 -2.61E-02
Ischemic stroke 8B11 Peripheral blood 1.51E-01 2.36E-02 1.21E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 2.84E-01 -1.96E-02 -7.35E-02
Lateral sclerosis 8B60.4 Cervical spinal cord 9.67E-01 9.14E-02 5.47E-01
Lateral sclerosis 8B60.4 Skin 5.78E-01 8.83E-02 2.75E-01
Liver cancer 2C12.0 Liver tissue 8.58E-23 2.43E-01 9.75E-01
Liver failure DB99.7-DB99.8 Liver tissue 4.67E-02 6.26E-01 5.98E+00
Lung cancer 2C25 Lung tissue 8.28E-01 -3.39E-03 -1.41E-02
Lupus erythematosus 4A40 Whole blood 1.75E-03 -2.86E-01 -3.96E-01
Major depressive disorder 6A70-6A7Z Whole blood 7.33E-01 -4.60E-02 -1.63E-01
Major depressive disorder 6A70-6A7Z Hippocampus 3.75E-01 -1.06E-02 -6.27E-02
Melanoma 2C30 Skin 2.22E-01 5.62E-01 7.13E-01
Multiple myeloma 2A83.1 Bone marrow 2.34E-05 -7.31E-01 -3.42E+00
Multiple myeloma 2A83.1 Peripheral blood 4.82E-02 8.62E-02 6.36E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 6.66E-01 9.61E-02 1.76E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 4.85E-01 4.29E-02 1.84E-01
Myelofibrosis 2A20.2 Whole blood 6.69E-04 2.54E-01 9.37E-01
Myocardial infarction BA41-BA50 Peripheral blood 5.44E-02 3.11E-01 5.05E-01
Myopathy 8C70.6 Muscle tissue 3.13E-01 -9.89E-02 -7.87E-01
Neonatal sepsis KA60 Whole blood 4.46E-03 -1.44E-01 -3.63E-01
Neuroectodermal tumour 2A00.11 Brain stem tissue 3.01E-03 -7.90E-01 -1.44E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 2.63E-01 -1.25E-01 -7.02E-01
Obesity related type 2 diabetes 5A11 Omental adipose tissue 8.13E-01 8.15E-02 5.69E-01
Olive pollen allergy CA08.00 Peripheral blood 2.57E-02 1.46E-01 7.38E-01
Oral cancer 2B6E Oral tissue 4.88E-07 -4.49E-01 -1.48E+00
Osteoarthritis FA00-FA0Z Synovial tissue 5.86E-01 1.66E-02 4.99E-02
Osteoporosis FB83.1 Bone marrow 3.50E-01 7.37E-02 3.14E-01
Ovarian cancer 2C73 Ovarian tissue 5.04E-01 -4.21E-02 -1.56E-01
Pancreatic cancer 2C10 Pancreas 4.36E-02 -2.23E-01 -7.23E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 2.69E-01 -9.08E-02 -4.66E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 3.28E-01 4.49E-02 2.28E-01
Pituitary cancer 2D12 Pituitary tissue 3.45E-01 6.96E-05 2.21E-04
Pituitary gonadotrope tumour 2D12 Pituitary tissue 8.48E-01 -2.33E-02 -7.56E-02
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 4.56E-01 -5.62E-03 -2.06E-02
Polycythemia vera 2A20.4 Whole blood 2.70E-08 3.13E-01 1.11E+00
Pompe disease 5C51.3 Biceps muscle 3.96E-01 -2.42E-02 -2.95E-01
Preterm birth KA21.4Z Myometrium 3.74E-01 1.62E-01 6.29E-01
Prostate cancer 2C82 Prostate 2.17E-02 -3.62E-01 -4.73E-01
Psoriasis EA90 Skin 3.58E-06 -2.91E-01 -6.89E-01
Rectal cancer 2B92 Rectal colon tissue 6.13E-01 -1.88E-01 -6.40E-01
Renal cancer 2C90-2C91 Kidney 1.37E-01 -1.60E+00 -1.16E+00
Retinoblastoma 2D02.2 Uvea 2.01E-05 -3.25E-01 -2.06E+00
Rheumatoid arthritis FA20 Synovial tissue 4.87E-01 3.39E-03 9.17E-03
Rhinovirus infection CA42.1 Nasal epithelium tissue 3.30E-01 -1.57E-02 -1.30E-01
Schizophrenia 6A20 Prefrontal cortex 3.98E-01 3.30E-02 1.08E-01
Schizophrenia 6A20 Superior temporal cortex 8.93E-01 -4.67E-02 -2.64E-01
Scleroderma 4A42.Z Whole blood 9.46E-02 -1.44E-01 -4.17E-01
Seizure 8A60-8A6Z Whole blood 7.90E-01 4.82E-02 1.91E-01
Sensitive skin EK0Z Skin 8.93E-01 -1.09E-01 -3.75E-01
Sepsis with septic shock 1G41 Whole blood 2.94E-01 -9.11E-03 -2.24E-02
Shwachman-Diamond syndrome 3A70.0 Bone marrow 7.29E-02 4.83E-01 9.15E-01
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 8.83E-02 1.02E-01 4.48E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 4.73E-01 7.40E-02 4.74E-01
Sjogren's syndrome 4A43.2 Salivary gland tissue 5.41E-01 -2.94E-01 -1.02E+00
Skin cancer 2C30-2C3Z Skin 4.46E-07 -3.79E-01 -6.61E-01
Thrombocythemia 3B63 Whole blood 1.36E-04 4.02E-01 1.38E+00
Thrombocytopenia 3B64 Whole blood 5.01E-01 -2.78E-02 -1.67E-01
Thyroid cancer 2D10 Thyroid 1.75E-05 8.06E-02 4.03E-01
Tibial muscular dystrophy 8C75 Muscle tissue 1.48E-01 -2.47E-01 -1.48E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 6.43E-01 4.62E-02 2.67E-01
Type 2 diabetes 5A11 Liver tissue 6.35E-01 -7.38E-02 -2.01E-01
Ureter cancer 2C92 Urothelium 7.19E-01 -1.94E-02 -7.05E-02
Uterine cancer 2C78 Endometrium tissue 3.62E-06 1.15E-01 3.28E-01
Vitiligo ED63.0 Skin 3.06E-01 -7.12E-02 -5.85E-01
------------------------------------------------------------------------------------
⏷ Show the Full List of Expression Under 107 Diseases

Drug Affinity of This DTP Assessed by Cell Line

Approved Drug(s)
Drug Name Highest Status Cell Line Affinity REF
Bumetanide Approved Proximal tubule (S2) cells-OAT4 Km = 306.0 microM [1]
Dinoprostone Approved Proximal tubule (S2) cells-OAT4 Km = 0.154 microM [2]
Methotrexate Approved Proximal tubule (S2) cells-OAT4 Km = 17.8 microM [6]
Pravastatin Approved Proximal tubule (S2) cells-OAT4 Km = 257.0 microM [7]
Tetracycline Approved Proximal tubule (S2) cells-OAT4 Km = 122.7 microM [8]
Zidovudine Approved Proximal tubule (S2) cells-OAT4 Km = 152.0 microM [9]
⏷ Show the Full List of 6 Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Highest Status Cell Line Affinity REF
PGF2alpha Clinical trial Proximal tubule (S2) cells-OAT4 Km = 0.692 microM [2]
Investigative Drug(s)
Drug Name Highest Status Cell Line Affinity REF
3R14S-OCHRATOXIN A Investigative Proximal tubule (S2) cells-OAT4 Km = 22.9 microM [10]
uric acid Investigative Human embryonic kidney cells (HEK293)-OAT4 Km = 106.0 microM [11]

References

1 Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
2 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
3 Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505.
4 The role of the intracellular glutamate gradient in driving organic anion transporter function.
5 Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.
6 Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
7 Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
8 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
9 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
10 Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75.
11 Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.